iCo Therapeutics, a Canada based biotechnology company, completed the merger with Satellos Bioscience, a regenerative medicine company. Financial terms were not disclosed. "We wish to express our gratitude for the ongoing support of the shareholders from both companies and welcome the new and returning shareholders who participated in the private placement financing associated with this transaction. The entire Satellos team is enthused by this leap forward in our capacity to become a global leader in the discovery and development of novel therapeutics with a particular emphasis on treating progressive, intractable degenerative muscle diseases for which treatment options are often quite limited," Frank Gleeson, Satellos Co-Founder, Director, President and CEO.